Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology.
Times cited: 68
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Times cited: 89